Top Abstract Purchase Related
Home
>
Node
>
Subnode

Osteoporosis induced either by unfractionated heparin or by low molecular weight heparin

Chigot, P.; De Gennes, C.; Samama, M.M.

Journal des Maladies Vasculaires 21(3): 121-125

1996

ISSN/ISBN: 0398-0499
PMID: 8965038
Document Number: 461497
Since the first suggestion of heparin-induced osteoporosis in 1963, a large body of work has been published. The mechanism can be explained by the effect of heparin as a cofactor for physiological stimulators of osteoclasts. Low-molecular weight heparins are an interesting alternative to non-fractionate heparin as the risk is reduced with an equivalent anticoagulation activity. Prevention is based on screening for patients at risk, preferential use of low-molecular weight heparins, early switch to anti-vitamin K and vitamin and calcium supplementation in pregnant women an elderly subjects. Curative treatment combines vitamin-calcium supplementation with inhibitors of bone resorption.

Document emailed within 1 workday
Secure & encrypted payments

Eriksson, E.; Wollter, I.M.; Christenson, B.; Stigendal, L.; Risberg, B. 1988: Heparin and fibrinolysis--comparison of subcutaneous administration of unfractionated and low molecular weight heparin Thrombosis and Haemostasis 59(2): 284-288
Godoy, I.; Herrera, C.; Zapata, C.; Kunstmann, S.; Abufhele, A.; Corbalán, R. 1998: Comparison of low-molecular-weight heparin and unfractionated heparin in the treatment of unstable angina Revista Medica de Chile 126(3): 259-264
Osterkorn, D.; Schramm, W.; Szucs, T. 1996: Health care economics evaluation of inpatient treatment of venous thrombosis with unfractionated heparin versus subcutaneous low molecular weight heparin at home Medizinische Klinik 91(9): 607-609
Ghali, W.A.; Pannatier, A.; Tsuyuki, R.T.; Hull, R.D.; MacKay, E.; Quan, H.; Cornuz, J. 2002: Transition from unfractionated heparin to low molecular weight heparins Thrombosis and Haemostasis 88(3): 539-540
Párama, J.A.; Llorens, R.; Sáenz de Buruaga, J.; Rocha, E. 1994: Low-molecular-weight heparin in a patient with heparin-induced thrombocytopenia and a cardiopulmonary bypass Medicina Clinica 102(16): 637-638
Huisse, M.G.; Huet, Y.; Zygelman, M.; Guillin, M.C. 1983: Thrombopenia induced by standard heparin. Therapeutic attempt using a low molecular weight heparin Presse Medicale 12(10): 643
Gouault-Heilmann, M.; Contant, G.; Pochmalicki, G.; Jan, F. 1984: Disseminated intravascular coagulation induced by heparin. Treatment with a combination of low-molecular weight heparin and concentrated antithrombin IIi Presse Medicale 13(22): 1393-1394
Brunkwall, J.; Mätzsch, T.; Bergqvist, D. 1990: The effect of unfractionated and low-molecular-weight heparin on the release of prostacyclin from the arterial wall Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis 1(6): 641-645
Iorio, A.; Agnelli, G. 2000: Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis Archives of Internal Medicine 160(15): 2327-2332
Brieger, D.; Dawes, J. 1996: Long-term persistence of biological activity following administration of Enoxaparin sodium (clexane) is due to sequestration of antithrombin-binding low molecular weight fragments--comparison with unfractionated heparin Thrombosis and Haemostasis 75(5): 740-746
Bannon, P.G.; Kim, M.J.; Dean, R.T.; Dawes, J. 1995: Augmentation of vascular endothelial barrier function by heparin and low molecular weight heparin Thrombosis and Haemostasis 73(4): 706-712
Uzan, A.; Marin, J.; Mardiguian, J.; Trillou, M.; Kiosseff, T.; Rougeot, C. 1987: Comparative pharmacokinetic study, in the dog, of low molecular weight heparin and standard heparin by labelling with 35S Annales Pharmaceutiques Francaises 45(6): 429-437
Nakagawa, M. 1993: Heparin, low molecular weight heparin, heparinoid, and antithrombin IIi therapy of disseminated intravascular coagulation Nihon Rinsho. Japanese Journal of Clinical Medicine 51(1): 87-92
Kaiser, B.; Hauptmann, J.; Markwardt, F. 1988: Experimental studies on the antithrombotic and haemorrhagic effects of heparin and a low molecular weight heparin derivative Folia Haematologica 115(1-2): 119-125
Bârzu, T.; Molho, P.; Tobelem, G.; Petitou, M.; Caen, J.P. 1984: Binding of heparin and low molecular weight heparin fragments to human vascular endothelial cells in culture Nouvelle Revue Francaise d'Hematologie 26(4): 243-247
Morita, Y.; Makino, H.; Ota, K.; Wada, J.; Shikata, K.; Kashihara, N.; Ikeda, S.; Ogura, T.; Ota, Z. 1994: Effect of heparin and low-molecular-weight heparin on proliferative glomerulonephritis Nihon Jinzo Gakkai Shi 36(7): 832-838
Hull, R.D.; Raskob, G.E.; Rosenbloom, D.; Pineo, G.F.; Lerner, R.G.; Gafni, A.; Trowbridge, A.A.; Elliott, C.G.; Green, D.; Feinglass, J. 1997: Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective Archives of Internal Medicine 157(3): 289-294
Mätzsch, T.; Bergqvist, D.; Blomquist, P.; Jiborn, H. 1987: Influence of standard heparin or low molecular weight heparin on healing of abdominal wounds and colonic anastomoses in rats Acta Chirurgica Scandinavica 153(10): 593-598
Mousa, S.A.; Fareed, J. 2001: Overview: from heparin to low molecular weight heparin: beyond anticoagulation Current Opinion in Investigational Drugs 2(8): 1077-1080
Wu, X.-x.; Chen, Y.; Tan, J.-p.; Liu, M.-l.; Zhang, J.-p. 2013: Modulation of low molecular weight heparin and heparin-binding epidermal growth factor on biological functions of human first trimester trophoblast Zhonghua Fu Chan Ke Za Zhi 48(2): 107-112